New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis
Authors:
- Fotios DrakopanagiotakisFDFotios Drakopanagiotakis
- Ilias PapanikolaouIPIlias Papanikolaou
- Theodoros PanouTPTheodoros Panou
- Elias GialafosEGElias Gialafos
- Nikolaos KostakisNKNikolaos Kostakis
- Konstantinos ChytopoulosKCKonstantinos Chytopoulos
- Anastasios BogiatzisABAnastasios Bogiatzis
- Paschalis SteiropoulosPaschalis Steiropoulos
Open Access
- 12 June 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5335
Abstract
Sarcoidosis is a multisystem granulomatous disorder of uncertain origin which still presents major therapeutic dilemmas. Longstanding dependence on corticosteroids, while effective for acute inflammation, carries considerable adverse effects over time. Advances in deciphering sarcoidosis pathobiology—including aberrant Janus kinase (JAK)- signal transducer and activator of transcription (STAT) signaling, mechanistic target of rapamycin (mTOR)-driven metabolic shifts, Th1/Th17.1 immune skewing, effector T-cell exhaustion, and granuloma-centered cytokine circuits—have revealed several targets for intervention. The treatment options are rapidly changing: the SARCORT trial showed that low-dose prednisolone is non-inferior to higher prednisolone doses; the pivotal PREDMETH trial validated methotrexate as a feasible first-line steroid-sparing option; efzofitimod, a novel immunomodulator targeting neuropilin-2, produced steroid-reducing effects in Phase IIbut not in Phase III trials; and JAK inhibitors are accumulating evidence across cutaneous and systemic presentations. The 2025 World Association for Sarcoidosis and Other Granulomatoses (WASOG) statement supports a move toward earlier steroid-sparing approaches. This review methodically connects sarcoidosis molecular and pathophysiological mechanisms to new targeted treatments, examines clinical trial evidence, and proposes future directions toward biomarker-driven individualized care.Keywords
This publication has 108 references indexed in Scilit:
- Sarcoidosis in the Genomic Era: From Genetic Drivers to Tailored TherapiesCurrent Allergy and Asthma Reports, 2025
- Use of Sirolimus, an mTOR Inhibitor, to Treat Sarcoidosis in Multiple SystemsJournal of Cardiovascular Translational Research, 2025
- Design of RESOLVE Lung, a multinational Phase 2, randomized, placebo-controlled trial of the anti-GM-CSF monoclonal antibody namilumab in patients with chronic pulmonary sarcoidosisContemporary Clinical Trials, 2025
- Integrative analysis of transcriptome and metabolome profiles reveals immune-metabolic alterations in pulmonary sarcoidosisMetabolomics, 2025
- Diagnostic Performance of CLEIA Versus FEIA for KL‐6 Peripheral and Alveolar Concentrations in Fibrotic Interstitial Lung Diseases: A Multicentre StudyJournal of Clinical Laboratory Analysis, 2024
- Factors Associated with Corticosteroid Adherence in SarcoidosisLung, 2024
- Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot StudyLung, 2023
- Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary SarcoidosisPulmonary Therapy, 2023
- Riociguat for Sarcoidosis-Associated Pulmonary HypertensionChest, 2022
- Inhibiting OX40 Restores Regulatory T-Cell Function and Suppresses Inflammation in Pulmonary SarcoidosisChest, 2021